Focused On-demand Library for UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NCR0

UPID:

B3GL2_HUMAN

Alternative names:

Beta-1,3-N-acetylgalactosaminyltransferase II

Alternative UPACC:

Q8NCR0; Q59GR3; Q5TCI3; Q96AL7

Background:

UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2, also known as Beta-1,3-N-acetylgalactosaminyltransferase II, plays a crucial role in the synthesis of unique carbohydrate structures on glycoproteins. It is specifically involved in the glycosylation of alpha-dystroglycan, a process essential for the binding of extracellular proteins with high affinity.

Therapeutic significance:

The protein's malfunction is linked to Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11, a severe disorder leading to early life fatality. Understanding its function could pave the way for novel therapeutic approaches targeting these debilitating conditions.